Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by CDCP1 is a transmembrane protein containing three extracellular CUB domains. Additionally we are shipping CUB Domain Containing Protein 1 Proteins (19) and CUB Domain Containing Protein 1 Kits (12) and many more products for this protein.
Showing 10 out of 218 products:
Human Polyclonal CDCP1 Primary Antibody for CyTOF, FACS - ABIN4900572
Kelly, Chan, Martinson, Kadoya, Ostertag, Ross, Richardson, Carpenter, DAmour, Kroon, Moorman, Baetge, Bang: Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. in Nature biotechnology 2011
Show all 2 Pubmed References
Human Polyclonal CDCP1 Primary Antibody for ELISA, WB - ABIN257697
Hooper, Zijlstra, Aimes, Liang, Claassen, Tarin, Testa, Quigley: Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. in Oncogene 2003
Show all 2 Pubmed References
Human Polyclonal CDCP1 Primary Antibody for IHC, IHC (p) - ABIN4296995
Iwata, Torok-Storb, Wayner, Carter: CDCP1 identifies a CD146 negative subset of marrow fibroblasts involved with cytokine production. in PLoS ONE 2014
CDCP1 knockdown reduced 3D invasion, which can be rescued by ACSL3 (show Acsl3 Antibodies) co-knockdown. In vivo, inhibiting CDCP1 activity with an engineered blocking fragment (extracellular portion of cleaved CDCP1) lead to increased LD abundance in primary tumors, decreased metastasis, and increased ACSL activity in two animal models of TNBC.
These results revealed that ADAM9 (show ADAM9 Antibodies) down-regulates miR-1 (show FSD1 Antibodies) via activating EGFR (show EGFR Antibodies) signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.
CDCP1 is a novel marker of the most aggressive N-positive triple-negative breast cancers; CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival
High expression level of CDCP1 is associated with recurrence in glioblastoma.
These studies have important implications for the development of a therapeutic to block CDCP1 activity and Triple-negative breast cancer (TNBC)metastasis.
CDCP1 may facilitate loss of adhesion by promoting activation of EGFR (show EGFR Antibodies) and Src (show SRC Antibodies) at sites of cell-cell and cell-substratum contact.
Stromal expression patterns for both ADAM12 (show ADAM12 Antibodies) and CDCP1.
these data demonstrated that HIF-2alpha (show EPAS1 Antibodies) could promote hepatocellular carcinoma cell migration by regulating CDCP1
Our results establish that differential glycosylation, cell surface presentation and extracellular expression of CDCP1 are hallmarks of prostate cancer progression.
High CDCP1 expression is associated with Colorectal Cancer.
Results indicate Cdcp1 (CD318) as a ligand of T-cell differentiation antigen CD6 (CD6 (show CD6 Antibodies)) and a potential target for the diagnosis and treatment of autoimmune diseases.
Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor (show RYK Antibodies) cross-talk in unanchored cells.
established mechanism for initiation of CDCP1-mediated signaling; demonstrated that processing of surface CDCP1 by extracellular serine proteases is prerequisite for CDCP1-dependent survival of cancer cells during metastasis; preventing cleavage of CDCP1 abrogated survival signaling associated with CDCP1 and induced PARP1 (show PARP1 Antibodies) cleavage and PARP1 (show PARP1 Antibodies)-mediated apoptosis
CDCP1 may have a role in neoplasm metastasis; targeting it with a monoclonal antibody inhibits metastasis in a prostate cancer model
The protein encoded by this gene is a transmembrane protein containing three extracellular CUB domains. This protein is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. This protein is located on the cell surface. It has been shown to be tyrosine phosphorylated in a cancer cell line. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
CUB domain-containing protein 1
, membrane glycoprotein gp140
, subtractive immunization M plus HEp3-associated 135 kDa protein
, transmembrane and associated with src kinases